Novalis Biotechnology Incubation

Novalis Biotechnology Incubation is a venture capital firm based in Ghent, Belgium, founded in 2018. The company is dedicated to seeding and supporting early-stage start-ups in the biotechnology and life sciences sectors. By providing essential funding and leveraging its extensive professional and academic networks, Novalis aids these start-ups in developing their business strategies and navigating the complexities of the industry. The firm's focus is on creating value for all stakeholders involved in the growth and success of the companies it incubates, fostering innovation and advancement within the healthcare landscape.

Jan Berghe

Managing Director and Co-Founder

14 past transactions

Modality.AI

Seed Round in 2024
Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Alithea Genomics

Seed Round in 2024
Alithea Genomics is a Switzerland-based company specializing in RNA sequencing and transcriptomics. Leveraging its expertise in bioengineering, molecular biology, and genomics, the company has developed proprietary technology aimed at enhancing the efficiency of Ribonucleic acid sequencing. This technology not only reduces operational costs but also significantly increases the throughput of analyzed samples. As a result, Alithea Genomics provides pharmaceutical companies with the tools necessary for advanced biomedical research and discoveries, enabling them to accelerate their development processes and improve research outcomes.

Altavo

Series A in 2024
Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.

Rarity Bioscience

Seed Round in 2023
Rarity Bioscience develops and provides multiplex assays to detect rare nucleic acid sequences in biological samples such as liquid biopsies. Its platform employs ultrasensitive molecular amplification technology, enabling both research and clinical applications.

C-mo Medical Solutions

Seed Round in 2023
C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.

Enzyre

Series A in 2022
Enzyre develops point-of-care diagnostic technology designed to bring lab testing capabilities to patients' homes or healthcare settings. Their device focuses on blood coagulation, measuring up to twelve reactions using a small volume of blood, improving patient quality of life without increasing healthcare costs.

Modality.AI

Seed Round in 2022
Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Carroucell

Series A in 2022
Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

Alithea Genomics

Seed Round in 2022
Alithea Genomics is a Switzerland-based company specializing in RNA sequencing and transcriptomics. Leveraging its expertise in bioengineering, molecular biology, and genomics, the company has developed proprietary technology aimed at enhancing the efficiency of Ribonucleic acid sequencing. This technology not only reduces operational costs but also significantly increases the throughput of analyzed samples. As a result, Alithea Genomics provides pharmaceutical companies with the tools necessary for advanced biomedical research and discoveries, enabling them to accelerate their development processes and improve research outcomes.

Trince

Seed Round in 2021
Trince specializes in advancing cell-based science and therapeutics. Its proprietary platform combines laser exposure with photothermal nanoparticles to facilitate the delivery of molecules into cells both in vitro and ex vivo, enabling efficient genetic material transfer.

Modality.AI

Seed Round in 2021
Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

RheaVita

Series A in 2021
RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products. Its platform combines all lyophilization steps into a single continuous production line with constant infeed and outfeed, addressing scale-up challenges and reducing cycle times. The approach enables faster formulation development, shorter time-to-market, and lower production costs, while supporting smaller manufacturing installations and reduced cleanroom space. The system promises enhanced quality assurance with potential for real-time release and aims to deliver consistent product quality and process uniformity across batches. The technology encompasses advanced lyophilization processes and GMP-compliant systems designed to overcome limitations of traditional batch freeze-drying and accelerate development timelines.

Grapheal

Seed Round in 2021
Grapheal is a Medtech startup specializing in embedded and wearable biosensors. Utilizing graphene transistors, their wireless sensors enable accurate field diagnostics and remote patient monitoring for various biomarkers and pathogens.

Enzyre

Debt Financing in 2020
Enzyre develops point-of-care diagnostic technology designed to bring lab testing capabilities to patients' homes or healthcare settings. Their device focuses on blood coagulation, measuring up to twelve reactions using a small volume of blood, improving patient quality of life without increasing healthcare costs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.